Home » Topics » Disease categories and therapies » Urology

Urology
RSS

JW Pharmaceutical reports desfesoterodine derivatives

Oct. 10, 2016

No Comments

Toray Industries prepares and tests agents for urinary incontinence

Oct. 6, 2016

No Comments

FDA grants orphan drug designation to AbbVie's atrasentan

Oct. 5, 2016

No Comments

Dimerix reports positive safety data for phase II trial of DMX-200

Oct. 5, 2016

No Comments

twoXAR collaborates with Mount Sinai researchers in diabetic nephropathy

Oct. 5, 2016

No Comments

Peloton Therapeutics describes HIF-2alpha inhibitors

Sep. 26, 2016

No Comments

Astellas Pharma and Kotobuki Pharmaceutical patent agents for nocturia

Sep. 23, 2016

No Comments

Regulus begins phase II trial of RG-012 in Alport syndrome

Sep. 22, 2016

No Comments

Bayer and Evotec establish 5-year research partnership in kidney disease

Sep. 22, 2016

No Comments

Promising phase II topline results for sparsentan in focal segmental glomerulosclerosis

Sep. 8, 2016

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Urology
RSS

JW Pharmaceutical reports desfesoterodine derivatives

Toray Industries prepares and tests agents for urinary incontinence

FDA grants orphan drug designation to AbbVie's atrasentan

Dimerix reports positive safety data for phase II trial of DMX-200

twoXAR collaborates with Mount Sinai researchers in diabetic nephropathy

Peloton Therapeutics describes HIF-2alpha inhibitors

Astellas Pharma and Kotobuki Pharmaceutical patent agents for nocturia

Regulus begins phase II trial of RG-012 in Alport syndrome

Bayer and Evotec establish 5-year research partnership in kidney disease

Promising phase II topline results for sparsentan in focal segmental glomerulosclerosis

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Urology RSS

Urology
RSS